Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

With annual revenue of $63.9 billion and a robust research pipeline, Merck continues to demonstrate its commitment to innovation in healthcare. This marks the first instance of a KEYTRUDA-based ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

With annual revenue of $63.9 billion and a robust research pipeline, Merck continues to demonstrate its commitment to innovation in healthcare. This marks the first instance of a KEYTRUDA-based ...

Merck recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said. Merck said last week its biggest ...